CTi Biopharma Corp

CTi Biopharma — Investor Presentation (November 2017)

32 slides from CTi Biopharma's investor presentation, Nov 13, 2017

  1. Slide 1: Corporate Presentation November 13, 2017

    © Copyright 2017 CTI BioPharma Corp. All rights reserved. Corporate Presentation November 13, 2017

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to a number of risks and uncertainties, the outcome of which could materially and/or a

  3. Slide 3: CTI BioPharma

    CTI BioPharma • Lead compound pacritinib (JAK2 inhibitor) - Seeking to address a significant unmet medical need in MF - Thrombocytopenia and/or prior exposure to JAK inhibitor including Jakafi/Jakavi (ruxolitinib) • New Management and Board Membership - President and CEO − Adam R Craig (Sunesis, TEV

  4. Slide 4: Smaller, Focused and Well Financed: Key Milestones 2017

    Smaller, Focused and Well Financed Key Milestones 2017 • Pacritinib  First patients enrolled in PAC203 myelofibrosis study  MAA submitted and under review for myelofibrosis (≤100,000/µL) • Pixuvri  Expansion of Servier Pixuvri collaboration with cost reductions  Completion of full enrollment of

  5. Slide 5: Our Pipeline – Hematology Focus

    Our Pipeline – Hematology Focus 5 Program Indication Phase 1 Phase 2 Phase 3 Approved Pacritinib PERSIST-1: Myelofibrosis (all platelet counts) PERSIST-2: Myelofibrosis (platelets ≤100,000/µL) PAC203: Myelofibrosis, patients - thrombocytopenia and prior ruxolitinib PIXUVRI® (pixantrone) Relapsed Agg

  6. Slide 6: Pacritinib

    Pacritinib • Second generation JAK inhibitor (JAK2) • Myelofibrosis unmet medical need - Thrombocytopenia - Prior ruxolitinib • Patent protection until 2026/2030 (plus term extension) • Orphan designation for myelofibrosis (US and EU) Seeking to expand the population of treatable MF patients 6

  7. Slide 7: Myelofibrosis

    Myelofibrosis 7 Impaired Blood Cell Production Thrombocytopenia, Anemia Prevalence 20K 28K Malignant bone marrow cancer with median survival 6 years after diagnosis; only approved therapy is Jakafi/Jakavi (ruxolitinib) Vannucchi, ASH Education Book, 2011; SmartAnalyst Quantitative Web survey (N=120)

  8. Slide 8: US/EU Ruxolitinib MF Sales

    US/EU Ruxolitinib MF Sales EU $345 MM US $550 MM Ruxolitinib MF Sales 2016 Average EU Net Pricing per month $4000 Average US Net Pricing per month $9000 8 Company estimates based on Novartis and Incyte 2016 year-end financial reports; BMO Capital Markets April 6, 2016; CB partners EU MF payer/pricin

  9. Slide 9: Ruxolitinib Discontinuations

    Ruxolitinib Discontinuations Poor survival following ruxolitinib discontinuation1,2 9 1. Newberry, Blood 2017; 2. Mehra, et al. ASH 2016 poster, Abstract 4769; 3. Cervantes, Blood 2012, Abstract 801; 4. Verstovek, Haematologica 2013. 50% of patients discontinue ruxolitinib by 3 years3,4 - Overall su

  10. Slide 10: Thrombocytopenia and ruxolitinib

    Significant declines in platelet counts with ruxolitinib at doses of 15-20mg BID1 1. Verstovsek, et al., Haematologica, 2015 May; 100(4): 479–488; 2. Ruxolinitib NDA Clinical Pharmacology and Biopharmaceutical Review(s), FDA 2011. 10 ….associated with dose reductions ….which potentially reduces clin

  11. Slide 11: Pacritinib Market Opportunity

    Pacritinib Market Opportunity Myelofibrosis Prevalence US/EU ~48,000¹ Ruxolitinib Naïve symptomatic ~19K1 Pacritinib US/EU Addressable MF Market ~18K - 19K patients Company estimates based on: 1. SmartAnalyst Quantitative Web survey (N=120); 2. 2015 ZS Pacritinib MD Treatment Flow US/EU5; 3. IMS Jak

  12. Slide 12: PAC203 Clinical Trial

    PAC203 Clinical Trial 12 Pacritinib 100 mg BID Primary or secondary myelofibrosis Prior ruxolitinib Platelet counts ≤100K / µL Randomization 1:1:1 Up to 105 patients Evaluate Safety and SVR at 12 and 24 weeks Pacritinib 100 mg QD Pacritinib 200 mg BID • Dose ranging study to support regulatory requi

  13. Slide 13: PERSIST-2 Phase 3 Myelofibrosis

    SVR, spleen volume reduction; TSS, total symptom score; *Cross-over from BAT allowed after assessment of the primary endpoint at week 24, or after progression; ** BAT may include ruxolitinib at the approved dose per its label. Pacritinib 200 mg BID Primary MF, ET-MF or PV-MF Platelets ≤100,000/µL Pr

  14. Slide 14: PERSIST-2: Efficacy Results

    PERSIST-2: Efficacy Results 14 Endpoint Statistics PAC BID+QD (N=149) PAC QD (N=75) Pac BID (N=74) BAT (N=72) SVR N (%) 27 (18.1) 11 (14.7) 16 (21.6) 2 (2.8) 95% CI 12.3-25.3 7.6-24.7 12.9-32.7 0.3-9.7 P value vs BAT 0.001 0.017 0.001 - TSS N (%) 37 (24.8) 13 (17.3) 24 (32.4) 10 (13.9) 95% CI 18.1-3

  15. Slide 15: Patients that Received Prior JAK Inhibitor

    Patients that Received Prior JAK Inhibitor 15 Efficacy Pac BID (N=33) Pac QD (N=33) BAT (N=34) SVR 18% 6% 3% TSS 30% 12% 15% Greater proportion of BID patients of those that had prior JAK inhibitor achieved endpoints SVR, ≥35% spleen volume reduction, TSS, ≥50% reduction in total symptom score at wk

  16. Slide 16: Patients that Received Ruxolitinib as BAT

    Patients that Received Ruxolitinib as BAT 16 Efficacy Pac BID (N=74) Pac QD (N=75) BAT: Rux (N=32) BAT: Other (N=40) SVR 22% 15% 3% 3% TSS 32% 17% 19% 10% SVR, ≥35% spleen volume reduction; TSS, ≥50% reduction in total symptom score at wk 24 from baseline; Harrison et al EHA 2017. Greater proportion

  17. Slide 17: PERSIST-2: Symptom Scores

    PERSIST-2: Symptom Scores 17 Better symptom relief with BID dosing Mascarenhas J, et al., ASH 2016. Abstract LBA-5.

  18. Slide 18: PERSIST-2: RBC Transfusions

    PERSIST-2: RBC Transfusions 18 Fewer RBC transfusions with BID dosing Mascarenhas J, et al., ASH 2016. Abstract LBA-5.

  19. Slide 19: PERSIST-2: Adverse Events (≥15%)

    PERSIST-2: Adverse Events (≥15%) 19 Adverse Event (%) PAC QD (N=104) PAC BID (N=106) BAT (N=98) Diarrhea 67 48 15 Nausea 38 32 11 Thrombocytopenia 33 34 23 Anemia 28 24 15 Vomiting 21 19 5 Fatigue 17 17 16 Peripheral Edema 13 20 15 Dizziness 14 15 5 Abdominal Pain 19 9 19 Pyrexia 11 15 3 Less GI tox

  20. Slide 20: PERSIST-2: Overall Survival

    PERSIST-2: Overall Survival 20 Data censored at date of clinical hold; Mascarenhas J, et al., ASH 2016. Abstract LBA-5. Overall Survival PAC QD (n=104) PAC BID (n=107) BAT (n=100) Events, n (%) 15 (14) 10 (9) 14 (14) Log-rank P value, vs BAT 0.662 0.346 - HR (95% CI), vs BAT 1.18 (0.57-2.44) 0.68 (0

  21. Slide 21: PERSIST-1 Phase 3 Myelofibrosis

    Primary MF, ET-MF or PV-MF Any platelet count No prior treatment with JAK2 inhibitors 2:1 Randomization n = 327 Primary Endpoint ≥35% SVR at Week 24 Best Available Therapy (BAT) excl. ruxolitinib Pacritinib 400 mg QD PERSIST-1 Phase 3 Myelofibrosis 21 • Multinational study in MF patients with any pl

  22. Slide 22: PERSIST-1: Spleen Volume Reduction

    PERSIST-1: Spleen Volume Reduction 22 SVR ≥35% at 24 weeks PAC BAT P-value Overall 19% (N=220) 5% (N=107) 0.0003 Platelets <100,000/µl 17% (N=72) 0% (N=34) 0.0086 <50,000/µl 23% (N=35) 0% (N=16) 0.045 *SVR, ≥35% spleen value reduction; Mesa RA, et al., Lancet Haematology 2017.

  23. Slide 23: PERSIST-1: ≥50% in TSS

    PERSIST-1: ≥50% in TSS 23 TSS, ≥50% reduction in total symptom score; *TSS 2.0; Mesa RA, et al., Lancet Haematology 2017. ≥50% in TSS* PAC QD (N=100) BAT (N=48) P-value Overall at 24 weeks 19% 10% 0.24 Overall at 48 weeks 15% 0% 0.0027

  24. Slide 24: PERSIST-1: Adverse Events (>10%)

    PERSIST-1: Adverse Events (>10%) 24 Adverse Event (%) PAC QD (N=220) BAT (N=106) Diarrhea 55 10 Nausea 27 7 Anemia 24 20 Thrombocytopenia 17 14 Vomiting 16 6 Fatigue 10 9 Abdominal Pain 10 9 Peripheral Edema 8 12 Pyrexia 5 10 Mesa RA, et al., Lancet Haematology 2017.

  25. Slide 25: PERSIST-1: Overall Survival

    PERSIST-1: Overall Survival 25 90% crossed over from BAT to PAC after 24 weeks Events, n(%) PAC QD 76(35) BAT 29(27) HR 1.36 (95% CI: 0.89, 2.09), P=0.158 Mesa RA, et al., Lancet Haematology 2017.

  26. Slide 26: Regulatory Strategy and Target Timelines

    Regulatory Strategy and Target Timelines FDA 26 2Q17 3Q17 4Q17 1Q18 2Q18 3Q18 4Q18 EMA MAA submission D180 LoQ D120 LoQ CHMP Opinion PAC203 interim PAC203 final • Pacritinib seeks to address a significant unmet medical need in MF • Thrombocytopenia (platelets <100,000/µL) • Prior exposure to JAK inh

  27. Slide 27: PIXUVRI: Approved in Europe

    PIXUVRI: Approved in Europe • Conditional approval in 2012 • 3rd - 4th line aggressive B-cell NHL • Partnered with Servier (ex-US) 27 ® ( P I X A N T R O N E )

  28. Slide 28: PIXUVRI: PIX306 Study

    PIXUVRI: PIX306 Study Relapse after CHOP-R or an equivalent regimen and ineligible for stem cell transplant 1:1 Randomization Primary Endpoint: PFS Secondary Endpoints: CR, ORR, OS Gemcitabine Rituximab Pixantrone Rituximab Phase 3 post-marketing commitment study • Aggressive B-cell NHL or Follicula

  29. Slide 29: Financial and Corporate

    Financial and Corporate

  30. Slide 30: Financial Overview

    Financial Overview Capital Structure and Financial Statistics Exchanges NASDAQ and MTA: CTIC Market Capitalization1 ~$130 mm Shares Outstanding as of 9/30/17 ~43mm Cash as of 9/30/17 ~$52.8mm Debt as of 9/30/17 ~$14.8mm 1. Based on stock price stock price of $3.02 per share as of November 6, 2017. 3

  31. Slide 31: Upcoming Milestones and Objectives

    Upcoming Milestones and Objectives • Pacritinib - Interim analysis of PAC203 - early 2018 - MAA questions with CHMP opinion - mid-2018 • Pixuvri - Top-line data on PIX306 - 1H2018 • Corporate - Cost efficiencies to lower cash burn in 2018 31

  32. Slide 32: Company Contact

    Company Contact: Ed Bell [email protected]

CTI Biopharma — Investor Presentation (November 2017) on 6ix